Clinical trials: Asthma Patients
Asthma
Safety, Efficacy, PK, and PD Characteristics of Orally Inhaled SB010 in Male Patients With Mild Asthma (Multiple Dose)
Asthma is a chronic inflammatory bronchial disorder with three distinct components: airway hyper-responsiveness (respiratory hypersensitivity), airway inflammation, and intermittent airway obstruction.
- Trial name
- NCT01743768
- Testing
- SB010
- Where
- 7 sites in Germany
- Volunteers
- 38 people
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Severe Asthma
PROPE Severe Asthma Study in Egypt
Asthma is a syndrome characterized by airway inflammation, reversible airway obstruction, and airway hyper-responsiveness. Patients present clinically with recurrent wheezing, shortness of breath, cough, and chest tightness.
- Trial name
- NCT06283290
- Where
- 4 sites in Egypt
- Volunteers
- 201 people
- Sponsor
- AstraZeneca
Asthma
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma
This randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study will evaluate the efficacy and safety of beclomethasone dipropionate (80 or 160 mcg/day) administered via breath-actuated inhaler…
- Trial name
- NCT02040766
- Testing
- Beclomethasone dipropionate BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI
- Where
- 102 sites in United States, Croatia and 3 more
- Volunteers
- 628 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
Primary Objective: The primary objective of the study is to characterize patients initiating DUPIXENT for asthma in a real-world setting, with respect to their medical history, including asthma history and asthma treatment…
- Trial name
- REVEAL (NCT04550962)
- Testing
- Dupilumab SAR231893
- Where
- 41 sites in Argentina, Chile and 10 more
- Volunteers
- 376 people
- Sponsor
- Sanofi
Asthma
Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations
A retrospective database analysis to evaluate the impact of omalizumab on the use of corticosteroid, emergency-department visits and hospitalizations among patients with uncontrolled asthma and using high-dose Inhaled…
- Trial name
- NCT01460862
- Sponsor
- Novartis Pharmaceuticals
Asthma
The Severity of Newly Diagnosed Asthma Patients and the Result of Initial 12 Weeks Treatment in China
The primary objective of the NIS is to evaluate the severity of newly diagnosed asthma patients based on Global Initiative for Asthma (GINA) severity category (GINA 2006 update).
- Trial name
- INITIAL (NCT02143739)
- Where
- 30 sites in China
- Volunteers
- 4,817 people
- Sponsor
- AstraZeneca
Asthma
Study to Investigate the Efficacy of Symbicort® SMART.
The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus…
- Trial name
- SAKURA (NCT00839800)
- Testing
- Symbicort Turbuhaler, Terbutaline Turbuhaler
- Where
- 109 sites in Argentina, Brazil and 10 more
- Volunteers
- 2,091 people
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease
Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF)
The purpose of this study is to characterise inspiratory flow parameters across 2 Easyhaler® (EH) inhaler versions and Diskus® inhaler in patients with asthma (including children, adults, and the elderly) and in patients with…
- Trial name
- SALIF (NCT01424137)
- Testing
- Easyhaler type A, Easyhaler type B, Diskus inhaler
- Where
- 5 sites in Estonia, Finland
- Volunteers
- 227 people
- Sponsor
- Orion Corporation, Orion Pharma
Uncontrolled Asthma
Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study
This study is a multi-centre, non-interventional, observational, ambispective registry. Planned study population consists of 9 000 adult patients with uncontrolled asthma receiving treatment according to standard of care (except…
- Trial name
- ICEBERG (NCT06521229)
- Where
- 44 sites in Russia
- Volunteers
- 9,000 people
- Sponsor
- AstraZeneca
Asthma
A Study for the Assessment of the Words Used by Patients and Physicians to Express Asthma Symptoms
The purpose of the study is to evaluate the concordance of the most frequently used words by the patients and the physicians to express asthma symptoms and the limitations of daily activities caused by asthma.
- Trial name
- NCT00986219
- Where
- 40 sites in Greece
- Volunteers
- 696 people
- Sponsor
- AstraZeneca
Diabetes, Hypertension
Quality IQ Patient Simulation Physician Practice Measurement and Engagement
This study will test the quality of physician care decisions using a patient-simulation based measurement and feedback approach that combines multiple-choice care decisions with real-time, personalized scoring and feedback.
- Conditions
- Diabetes, Hypertension, Depression, Osteoarthritis
- Trial name
- Q-IQ (NCT03800901)
- Testing
- Continuing Medical Education, Quality IQ Patient Simulations
- Where
- United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Asthma
Asthma Control Test Guided Treatment in Chinese Subjects
This study is aimed to evaluate the effectiveness of Asthma Control Test (ACT) guided treatment compared with usual care in asthma subjects in China.
- Trial name
- NCT02868281
- Testing
- ACT guided Routine Treatment, Routine Treatment
- Where
- 6 sites in China
- Volunteers
- 530 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma
This Phase II, randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of lebrikizumab on airway eosinophilic inflammation in participants with uncontrolled asthma who are using inhaled…
- Trial name
- NCT02099656
- Testing
- Lebrikizumab, Inhaled corticposteroids (ICS), Second Asthma Controller Medication
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 64 people
- Sponsor
- Hoffmann-La Roche
Asthma
Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia
The purpose of this study is to compare whether Symbicort Maintenance \& Reliever Therapy (SMART) is more effective in uncontrolled asthmatic patients than their current therapy in a real life situation.
- Trial name
- SMARTASIA (NCT00939341)
- Testing
- Symbicort (Budesonide/Formoterol)
- Where
- 35 sites in China, India and 3 more
- Volunteers
- 862 people
- Sponsor
- AstraZeneca
Severe Eosinophilic Asthma
Real World Study With Benralizumab in Severe Asthma in Switzerland
BEEPS describes the utility of patient reported outcomes (PRO) as simple, pragmatic, and sensitive tool to assess early treatment response of benralizumab to document the level of asthma control and change in medication after 1…
- Trial name
- BEEPS (NCT03907137)
- Where
- 12 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Asthma
Efficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence
The goal of this observational study is to determine if using the SiA® (Systematic Intervention Agent) system can improve inhaler technique and medication adherence in adults with asthma who are already using Trimbow pMDI…
- Trial name
- SiASMARTer (NCT06908421)
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Chiesi Pharma AB, Nordic
Eosinophilic Asthma
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients…
- Trial name
- NCT01270464
- Testing
- Reslizumab
- Where
- 89 sites in United States, Argentina and 11 more
- Volunteers
- 315 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma, Pulmonary Disease, Chronic Obstructive
Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler Inhalers
The aim of the study is to measure the inspiratory flow that the different patient groups (asthmatic children, adults and elderly, as well as chronic obstructive pulmonary disease (COPD) patients) generate through empty Easyhaler…
- Trial name
- PIFECO (NCT00984906)
- Testing
- Empty inhalers
- Where
- 4 sites in Finland, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Orion Corporation, Orion Pharma
Asthma
A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health Service
Asthma is a common lung condition that causes occasional breathing difficulties and affects around 5.4 million people in the UK of all ages.
- Trial name
- REMISSION UK (NCT06261567)
- Testing
- Biologic treatment
- Where
- 4 sites in United Kingdom
- Volunteers
- 415 people
- Sponsor
- AstraZeneca
Asthma
Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)
Ciclesonide is a novel inhaled corticosteroid for the treatment of asthma. In this study the effect of ciclesonide on airway hyperresponsiveness (AHR), exhaled nitric oxide (NO), and induced sputum inflammatory biomarkers will be…
- Trial name
- NCT00546520
- Testing
- Ciclesonide
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- AstraZeneca